

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated October 19, 2020.

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on October 19, 2020 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk receives confirmation from Health Canada of receipt of interim order application and provides corporate update.

Item 5. Full Description of Material Change

Vancouver, British Columbia – October 19, 2020 - Blackhawk Growth Corp(CSE:BLR) (the “**Corporation**” or “**Blackhawk**”), is pleased to provide the following corporate update.

The Health Canada Interim Order (“IO”) application was completed and submitted for the ExProbe SARS-CoV-2 Testing Kit. The Company received confirmation of receipt from Health Canada on October 14, 2020. Even though Blackhawk cannot guarantee timelines, the anticipated time to process the application is between 40 and 60 days.

The IO process for the SARS-CoV-2 IgG/IgM Rapid Test Kit is scheduled to be submitted as soon as it is completed. The application process, though similar, has many more parameters and thus requires more time to prepare. Health Canada timelines will vary on a case by case basis for an IO application review. As we understand, currently this duration is closer to 4 weeks from the time of submission but could take longer depending on the extent of information requests received from Health Canada.

Blackhawk makes no representations or provide any guarantees on Health Canada review timelines, or that any particular application will be successful.

We would also like to confirm that Blackhawk has obtained its Medical Device Establishment License (MDEL) and will be acting as the agent for the manufacturer in

Canada. The ExProbe SARS-CoV-2 Testing Kit was submitted with Blackhawk as the agent.



id: 162228

Licence Number **15228** Numéro de la licence

**Medical Device
Establishment Licence**

**Licence d'établissement
pour les instruments médicaux**

BLACKHAWK GROWTH CORP.

SUITE 303 - 750 PENDER STREET
VANCOUVER, BRITISH COLUMBIA
CANADA
V6C 2T7

This licence is issued in accordance with the Medical Devices Regulations of the Food and Drugs Act for the following activities:

Cette licence est délivrée conformément à la Loi sur les aliments et drogues, règlement sur les instruments médicaux pour les activités qui suivent:

NuWave Foods

NuWave is expecting to receive the finalized contract for its larger-scale equipment this week as negotiations have completed. NuWave has added multiple baked goods to its exclusivity to be produced in its Edmonton facility. NuWave has also added exclusivity for the drying of psilocybin mushrooms internationally where regulations or licencing allow. The Company will provide further updates when they become available.

Trip Pharma

Trip Pharma has secured the location for its first Canadian clinic. The clinic will be Situated on a prominent corner of the warehouse district in Edmonton's historic MacCosham building. Modifications and outfitting are currently underway. Trip Pharma plans to keep the character of the original architectural features including the heavy wooden beams and columns, brick walls, hardwood floors and heavy timber ceilings. Utilizing just under 5,000 Sq feet on the main and second floors, the clinic is spacious enough for exam rooms built for the post-pandemic era. Initial staff has been secured and Dr. Krista Leicht intends to move her current practice to this facility as soon as upgrades have been completed. At capacity, the clinic will be able to support 11 medical professionals. The intended occupants of this clinic will be Psychiatrists, Psychologists, and General Practitioners. Blackhawk's "*Talk to Doc*" platform will be the official telemedicine platform for the Trip Pharma clinic.

Picture of the clinic below – more pictures will be available upon completion of the upgrades.



For further information please contact:
Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7. Omitted Information

Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

October 19, 2020